Locus Biosciences

Locus Biosciences is a clinical-stage biotechnology company developing engineered bacteriophage products to address critical unmet medical needs in bacterial infections and immunology. The LOCUS platform combines predictive artificial intelligence and automated robotics to deliver optimized precision phage therapies that specifically kill target pathogens while leaving non-target bacteria (i.e., the rest of the patient’s microbiome) unaffected. Locus has strong backing from partners, having signed contracts with BARDA and CARB-X. The company recently completed the open-label portion of a Phase 2 trial assessing LBP-EC01 for the treatment of uncomplicated UTIs caused by drug-resistant E. coli.